N-0877 / Eurofarma - LARVOL DELTA

ATHESA: Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Eurofarma Laboratorios S.A. | N=292 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Final Report on NCCTG N0877 (Alliance): A Phase II Randomized, Placebo-Controlled Trial of Chemoradiotherapy with or without Dasatinib for Glioblastoma. (PubMed, Neuro Oncol) - "The addition of dasatinib to standard chemoradiation did not improve outcomes for patients with glioblastoma."

Journal • P2 data • Brain Cancer • Glioblastoma • Hematological Disorders • Oncology • Solid Tumor